Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issues-Reference-Cited by-同舟云学术

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issues

Published:2011-04 Issue:1 Volume:72 Page:3-8
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Gridelli C.,De Marinis F.,Di Maio M.,Cortinovis D.,Cappuzzo F.,Mok T.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference34 articles.

1. Epidermal growth factor-related peptides and their receptors in human malignancies;Salomon;Crit Rev Oncol Hematol,1995

2. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

3. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

4. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib;Pao;Proc Natl Acad Sci USA,2004

5. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan;Huang;Clin Cancer Res,2004

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CIB2 mediates acquired gefitinib resistance by inducing ZEB1 expression and epithelial-mesenchymal transition;Aging;2024-09-10

2. Futuro diagnóstico y terapéutico del cáncer de pulmón de células no pequeñas con alteraciones genómicas;Medicina;2023-12-31

3. Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer;Cancer Letters;2023-06

4. Anti-TGF-β1 aptamer enhances therapeutic effect of tyrosine kinase inhibitor, gefitinib, on non-small cell lung cancer in xenograft model;Molecular Therapy - Nucleic Acids;2022-09

5. 18F-Fluorodeoxyglucose PET/CT for Early Prediction of Outcomes in Patients with Advanced Lung Adenocarcinomas and EGFR Mutations Treated with First-Line EGFR-TKIs;Cancers;2022-03-15